EOLS:NSD-Evolus, Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 12.22

Change

-1.54 (-11.19)%

Market Cap

USD 0.46B

Volume

1.67M

Average Target Price

USD 11.14 (-8.81%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-04 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CGC Canopy Growth Corporation

-2.23 (-6.71%)

USD12.62B N/A N/A
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
APHA Aphria Inc

-1.47 (-8.09%)

USD5.75B 60.80 454.68
TLRY Tilray, Inc

-2.64 (-10.44%)

USD4.34B N/A N/A
CRON Cronos Group Inc

-0.67 (-6.50%)

USD3.71B 37.00 N/A
PCRX Pacira BioSciences, Inc

-2.13 (-3.07%)

USD3.01B 20.83 68.83
SNDL Sundial Growers Inc

-0.14 (-10.77%)

USD2.03B -99,999.99 N/A
ORGO Organogenesis Holdings Inc

-0.83 (-5.38%)

USD1.97B 456.50 145.92
IRWD Ironwood Pharmaceuticals, Inc

+0.02 (+0.20%)

USD1.60B 15.11 11.95

ETFs Containing EOLS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 263.69% 100% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 263.69% 100% A+ 99% A+
Trailing 12 Months  
Capital Gain 74.32% 88% B+ 76% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 74.32% 88% B+ 76% C
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -14.85% 31% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.85% 31% F 10% F
Risk Return Profile  
Volatility (Standard Deviation) 63.49% 26% F 21% F
Risk Adjusted Return -23.40% 41% F 21% F
Market Capitalization 0.46B 57% F 49% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 11.65 25% F 17% F
Price / Cash Flow Ratio -4.97 60% D- 65% D
EV/EBITDA 0.12 96% A 96% A
Management Effectiveness  
Return on Equity -256.35% 10% F 4% F
Return on Invested Capital -58.60% 35% F 16% F
Return on Assets -21.45% 39% F 18% F
Debt to Equity Ratio 115.10% 29% F 19% F
Technical Ratios  
Short Ratio 3.68 38% F 33% F
Short Percent 14.63% 25% F 12% F
Beta 2.54 9% F 7% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector